Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1203pxs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 3	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 4	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 5	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 6	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 7	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 8	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 9	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 10	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS 11	JUL 28	CA/CAplus patent coverage enhanced
NEWS 12	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 13	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 14	JUL 28	STN Viewer performance improved
NEWS 15	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS 16	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 17	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS 18	AUG 15	CAplus currency for Korean patents enhanced
NEWS 19	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS 20	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS 21	SEP 25	CA/CAplus current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS 22	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and and Korean patents enhanced
NEWS 23	SEP 29	IFICLS enhanced with new super search field
NEWS 24	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS 25	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents
NEWS 26	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS 27	OCT 07	Multiple databases enhanced for more flexible patent number searching

```
 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:22:34 ON 07 OCT 2008

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 14:22:41 ON 07 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    6 OCT 2008  HIGHEST RN 1057750-28-3
DICTIONARY FILE UPDATES:   6 OCT 2008  HIGHEST RN 1057750-28-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10846978.str
```





chain nodes :
10 17 24
ring nodes :
1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 18 19 20 21 22 23
chain bonds :
1-11 5-18 8-10 12-17 21-24
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 11-12 11-16 12-13 13-14 14-15
15-16 18-19 18-23 19-20 20-21 21-22 22-23
exact/norm bonds :
2-7 3-9 5-18 7-8 8-9 18-19 18-23 19-20 20-21 21-22 22-23
exact bonds :
1-11 8-10 12-17 21-24
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 exa
SAMPLE SEARCH INITIATED 14:23:00 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        1 TO ITERATE

100.0% PROCESSED        1 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            1 TO       80
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA EXA SAM L1

=> s l1 ful
FULL SEARCH INITIATED 14:23:04 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      307 TO ITERATE

100.0% PROCESSED      307 ITERATIONS                                4 ANSWERS
SEARCH TIME: 00.00.01

L3            4 SEA SSS FUL L1

=> d l3 1-4

L3   ANSWER 1 OF 4  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   476148-82-0  REGISTRY
ED   Entered STN:  13 Dec 2002
CN   Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-,
```

hydrochloride, hydrate (1:1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, monohydrochloride, monohydrate (9CI)
MF C17 H17 F N4 S . Cl H . H2 O
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL
CRN (99487-25-9)



● HCl

● H_2O

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2008 ACS on STN
RN 109348-38-1 REGISTRY
ED Entered STN: 25 Jul 1987
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:?) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (9CI)
MF C17 H17 F N4 S . x Cl H
SR CA
LC STN Files: BIOTECHNO, CA, CAPLUS, EMBASE, PROUSDDR, SYNTHLINE
CRN (99487-25-9)



● x HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2008 ACS on STN
RN 99487-26-0 REGISTRY
ED Entered STN: 21 Dec 1985
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, monohydrochloride (9CI)
OTHER NAMES:
CN MCI 225
DR 135991-48-9
MF C17 H17 F N4 S . Cl H
SR CA
LC STN Files: ADISINSIGHT, BIOSIS, BIOTECHNO, CA, CAPLUS, CHEMCATS, CIN, EMBASE, IMSDRUGNEWS, IMSRESEARCH, MEDLINE, PHAR, PROMT, PROUSDDR, RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
CRN (99487-25-9)



● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

20 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
20 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2008 ACS on STN
RN 99487-25-9 REGISTRY
ED Entered STN: 21 Dec 1985
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-
(CA INDEX NAME)
MF C17 H17 F N4 S
CI COM
SR CA
LC STN Files: BIOTECHNO, CA, CAPLUS, CHEMCATS, EMBASE, PHAR, PROUSDDR,
SYNTHLINE, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

16 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
16 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file uspatfull
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 186.36 186.57

FILE 'USPATFULL' ENTERED AT 14:23:31 ON 07 OCT 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 7 Oct 2008 (20081007/PD)
FILE LAST UPDATED: 7 Oct 2008 (20081007/ED)
HIGHEST GRANTED PATENT NUMBER: US7434267
HIGHEST APPLICATION PUBLICATION NUMBER: US20080244796
CA INDEXING IS CURRENT THROUGH 7 Oct 2008 (20081007/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 7 Oct 2008 (20081007/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2008
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2008

USPATFULL now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

=> s l3
L4 39 L3

=> s l4 and cancer
150861 CANCER
L5 22 L4 AND CANCER

=> d l5 1-22 ibib, abs, hitstr

L5 ANSWER 1 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2008:214787 USPATFULL
TITLE: Modulation of Neurogenesis with Biguanides and GSK3-beta Agents
INVENTOR(S): Barlow, Carrolee, Del Mar, CA, UNITED STATES
Carter, Todd, San Diego, CA, UNITED STATES
Morse, Andrew, San Diego, CA, UNITED STATES
Treuner, Kai, San Diego, CA, UNITED STATES
Lorrain, Kym I., San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080188457	A1	20080807
APPLICATION INFO.:	US 2008-24923	A1	20080201 (12)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2007-888030P	20070202 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 4365
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of one or more biguanides in combination with one or more GSK3-β agents, to stimulate or activate the formation of new nerve cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2008:196095 USPATFULL
TITLE: Modulation Of Neurogenesis With Use of Modafinil
INVENTOR(S): Barlow, Carrolee, Del Mar, CA, UNITED STATES
Carter, Todd A., San Diego, CA, UNITED STATES
Morse, Andrew, San Diego, CA, UNITED STATES
Treuner, Kai, San Diego, CA, UNITED STATES
Lorrain, Kym I., San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080171750	A1	20080717
APPLICATION INFO.:	US 2008-972467	A1	20080110 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2007-884584P	20070111 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US

NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 4561
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of modafinil, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2008:190961 USPATFULL
TITLE: Modulation of Neurogenesis By Melatoninergic Agents
INVENTOR(S): Barlow, Carrolee, Del Mar, CA, UNITED STATES
Carter, Todd A., San Diego, CA, UNITED STATES
Morse, Andrew, San Diego, CA, UNITED STATES
Treuner, Kai, San Diego, CA, UNITED STATES
Lorrain, Kym I., San Diego, CA, UNITED STATES
Redwine, Jeff, San Diego, CA, UNITED STATES
Hoffmaster, Christine, El Cajon, CA, UNITED STATES
PATENT ASSIGNEE(S): BrainCells, Inc, San Diego, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080167363	A1	20080710
APPLICATION INFO.:	US 2007-965110	A1	20071227 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-882434P	20061228 (60)
	US 2006-882440P	20061228 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US
NUMBER OF CLAIMS: 51
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 4901
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of melatonin or other melatoninergic agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2008:190889 USPATFULL
TITLE: NEUROGENESIS BY MODULATING ANGIOTENSIN
INVENTOR(S): Barlow, Carolee, Del Mar, CA, UNITED STATES
Carter, Todd A., San Diego, CA, UNITED STATES
Treuner, Kai, San Diego, CA, UNITED STATES
Lorrain, Kym I., San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES (U.S.

corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080167291	A1	20080710
APPLICATION INFO.:	US 2007-746539	A1	20070509 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-746859P	20060509 (60)
	US 2006-807594P	20060717 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Page(s)
LINE COUNT: 5191
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The invention includes compositions and methods based on modulation angiotensin activity to stimulate or activate the formation of new nerve cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2008:175983 USPATFULL
TITLE: COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND ACETYLCHOLINESTERASE INHIBITION
INVENTOR(S): Lange, Josephus H.M., Weesp, NETHERLANDS
Kruse, Cornelis G., Weesp, NETHERLANDS
Shadid, Belal, Weesp, NETHERLANDS
PATENT ASSIGNEE(S): Solvay Pharmaceuticals B.V. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080153867	A1	20080626
APPLICATION INFO.:	US 2007-957948	A1	20071217 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-875808P	20061220 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 1612
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Embodiments of this invention relate to compounds having a combination of cannabinoid-CB.sub.1 antagonism and cholinesterase inhibition, to pharmaceutical compositions comprising these compounds, to methods for preparing these compounds, methods for preparing novel intermediates useful for the synthesis of these compounds, and methods for preparing compositions comprising these compounds. The invention also relates to methods of treating Alzheimer's disease, cognitive disorders, memory disorders, dementia, attention deficit disorder, traumatic brain injury, drug dependence, addiction or substance abuse by administering a

pharmaceutical composition comprising these compounds to a patient in need thereof. A compound with a combination of cannabinoid-CB.sub.1 antagonism and cholinesterase inhibition is a compound of formula (1)

##STR1##

wherein the symbols have the meanings given in the specification.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 99487-26-0DP, MCI-225, pharmacophoric element, conjugates with CB1 antagonist pharmacophoric element
(preparation of compds. with both CB1 receptor antagonistic and acetylcholinesterase inhibiting activities)
RN 99487-26-0 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L5 ANSWER 6 OF 22 USPATFULL on STN

ACCESSION NUMBER:	2008:124776 USPATFULL
TITLE:	MELANOCORTIN RECEPTOR MEDIATED MODULATION OF NEUROGENESIS
INVENTOR(S):	Barlow, Carrolee, Del Mar, CA, UNITED STATES Carter, Todd A., San Diego, CA, UNITED STATES Morse, Andrew, San Diego, CA, UNITED STATES Treuner, Kai, San Diego, CA, UNITED STATES Lorrain, Kym I., San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S):	BrainCells, Inc., San Diego, CA, UNITED STATES, 92121 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080108574	A1	20080508
APPLICATION INFO.:	US 2007-862115	A1	20070926 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-827202P	20060927 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US
NUMBER OF CLAIMS:	25
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	3 Drawing Page(s)

LINE COUNT: 5671
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present disclosure describes compositions and methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a melanocortin receptor (MCR) modulating agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2008:118467 USPATFULL
TITLE: PPAR MEDIATED MODULATION OF NEUROGENESIS
INVENTOR(S): Barlow, Carrolee, Del Mar, CA, UNITED STATES
Carter, Todd A., San Diego, CA, UNITED STATES
Morse, Andrew, San Diego, CA, UNITED STATES
Treuner, Kai, San Diego, CA, UNITED STATES
Lorrain, Kym I., San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080103165	A1	20080501
APPLICATION INFO.:	US 2007-857221	A1	20070918 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-826206P	20060919 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 5050
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system including by stimulating or increasing neurogenesis, neuroproliferation, and/or neurodifferentiation. The disclosure includes compositions and methods based on use of a peroxisome proliferator-activated receptor (PPAR) agent, optionally in combination with one or more other neurogenic agents, to stimulate or increase a neurogenic response and/or to treat a disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2008:118408 USPATFULL
TITLE: HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS
INVENTOR(S): Barlow, Carrolee, Del Mar, CA, UNITED STATES
Carter, Todd A., San Diego, CA, UNITED STATES
Morse, Andrew, San Diego, CA, UNITED STATES
Treuner, Kai, San Diego, CA, UNITED STATES
Lorrain, Kym I., San Diego, CA, UNITED STATES
Redwine, Jeff, San Diego, CA, UNITED STATES
Hoffmaster, Christine, Lakeside, CA, UNITED STATES
PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES (U.S.

corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080103105	A1	20080501
APPLICATION INFO.:	US 2007-858790	A1	20070920 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-826710P	20060922 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Page(s)
LINE COUNT: 5234
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The instant disclosure describes methods of treating diseases and conditions of the central and peripheral nervous system including by stimulating or increasing neurogenesis, neuroproliferation, and/or neurodifferentiation. The disclosure includes compositions and methods based on use of an HMGCR modulating agent, optionally in combination with one or more other neurogenic agents, to stimulate or increase a neurogenic response and/or to treat disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2008:73637 USPATFULL
TITLE: COMBINATIONS CONTAINING A 4-ACYLAMINOPYRIDINE DERIVATIVE
INVENTOR(S): Barlow, Carrolee, Del Mar, CA, UNITED STATES
Carter, Todd A., San Diego, CA, UNITED STATES
Morse, Andrew, San Diego, CA, UNITED STATES
Treuner, Kai, San Diego, CA, UNITED STATES
Lorrain, Kym I., San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080064671	A1	20080313
APPLICATION INFO.:	US 2007-766721	A1	20070621 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-825080P	20060908 (60)
	US 2006-868510P	20061204 (60)
	US 2007-884584P	20070111 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 4635
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The instant disclosure describes compositions and methods for treating diseases and conditions of the central and peripheral nervous system.

The disclosure includes compositions and methods based on use of a 4-acylaminopyridine derivative in combination with one or more other neurogenic agents. One 4-acylaminopyridine derivative is MKC-231.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2007:309347 USPATFULL
TITLE: 5 HT RECEPTOR MEDIATED NEUROGENESIS
INVENTOR(S): Barlow, Carrolee, Del Mar, CA, UNITED STATES
Carter, Todd, San Diego, CA, UNITED STATES
Morse, Andrew, San Diego, CA, UNITED STATES
Treuner, Kai, San Diego, CA, UNITED STATES
Lorrain, Kym I., San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070270449	A1	20071122
APPLICATION INFO.:	US 2007-746008	A1	20070508 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-746878P	20060509 (60)
	US 2006-805436P	20060621 (60)
	US 2006-882429P	20061228 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US
NUMBER OF CLAIMS: 47
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 53 Drawing Page(s)
LINE COUNT: 5284
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a 5HTR agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 11 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2007:291200 USPATFULL
TITLE: Soluble salts of thieno[2,3-d]pyrimidine derivatives
INVENTOR(S): Cooper, Martin Ian, Cambridgeshire, UNITED KINGDOM
Frampton, Christopher Stephen, Suffolk, UNITED KINGDOM
PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., Waltham, MA, UNITED STATES, 02451 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070254899	A1	20071101
APPLICATION INFO.:	US 2007-728966	A1	20070327 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-788565P	20060331 (60)
	US 2006-808905P	20060526 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, LLP, ONE POST OFFICE SQUARE, BOSTON, MA, 02109-2127, US
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 2940
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to novel salts of thieno[2,3-d]pyrimidine derivatives, including 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts. The present invention is also directed to compositions including such polymorphs and methods for using such salts, e.g., in the treatment of gastrointestinal and/or genitourinary disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 99487-26-0, MCI-225
(soluble salts of thienopyrimidine derivs., and therapeutic use)
RN 99487-26-0 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 99487-25-9D, salts
(soluble salts of thienopyrimidine derivs., and therapeutic use)
RN 99487-25-9 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



IT 99487-25-9
(soluble salts of thienopyrimidine derivs., and therapeutic use)
RN 99487-25-9 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-

(CA INDEX NAME)



L5 ANSWER 12 OF 22 USPATFULL on STN

ACCESSION NUMBER:	2007:291192 USPATFULL		
TITLE:	Crystalline forms of 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine		
INVENTOR(S):	Cooper, Martin Ian, Cambridgeshire, UNITED KINGDOM Frampton, Christopher Stephen, Suffolk, UNITED KINGDOM		
PATENT ASSIGNEE(S):	Dynogen Pharmaceuticals, Inc., Waltham, MA, UNITED STATES, 02451 (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070254891	A1	20071101
APPLICATION INFO.:	US 2007-728947	A1	20070327 (11)
	NUMBER		DATE
PRIORITY INFORMATION:	US 2006-788338P		20060331 (60)
	US 2006-808603P		20060526 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, LLP, ONE POST OFFICE SQUARE, BOSTON, MA, 02109-2127, US		
NUMBER OF CLAIMS:	33		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	11 Drawing Page(s)		
LINE COUNT:	3877		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to novel crystalline forms of 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts, including 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine hydrochloride crystalline forms. The present invention is also directed to compositions including such crystalline forms and methods for making and using such crystalline forms, e.g., in the treatment of gastrointestinal and/or genitourinary disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99487-25-9D, salts 99487-26-0, MCI-225
(stable crystalline forms of 4-(2-fluorophenyl)-6-Me-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts for dosage forms)

RN 99487-25-9 USPATFULL

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



RN 99487-26-0 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L5 ANSWER 13 OF 22 USPATFULL on STN

ACCESSION NUMBER:	2007:278709 USPATFULL
TITLE:	MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS
INVENTOR(S):	Barlow, Carrolee, Del Mar, CA, UNITED STATES Carter, Todd A., San Diego, CA, UNITED STATES Morse, Andrew, San Diego, CA, UNITED STATES Treuner, Kai, San Diego, CA, UNITED STATES Lorrain, Kym I., San Diego, CA, UNITED STATES Gitnick, Dana, San Marcos, CA, UNITED STATES Pires, Jammieson C., San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S):	BrainCells, Inc, San Diego, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070244143	A1	20071018
APPLICATION INFO.:	US 2007-683982	A1	20070308 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-805440P	20060621 (60)
	US 2006-780415P	20060308 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US
NUMBER OF CLAIMS:	20
EXEMPLARY CLAIM:	1

NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 4135
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of melatonin or other nootropic agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 14 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2007:237654 USPATFULL
TITLE: MODULATION OF NEUROGENESIS BY PDE INHIBITION
INVENTOR(S): Barlow, Carrolee, Del Mar, CA, UNITED STATES
Carter, Todd A., San Diego, CA, UNITED STATES
Lorrain, Kym I., San Diego, CA, UNITED STATES
Pires, Jammieson C., San Diego, CA, UNITED STATES
Treuner, Kai, San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070208029	A1	20070906
APPLICATION INFO.:	US 2006-551667	A1	20061020 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-729366P	20051021 (60)
	US 2006-784605P	20060321 (60)
	US 2006-807594P	20060717 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 4538
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a PDE agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 15 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2007:128661 USPATFULL
TITLE: GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS
INVENTOR(S): Barlow, Carrolee, Del Mar, CA, UNITED STATES
Carter, Todd A., San Diego, CA, UNITED STATES
Morse, Andrew, San Diego, CA, UNITED STATES
Lorrain, Kym I., San Diego, CA, UNITED STATES
Pires, Jammieson C., San Diego, CA, UNITED STATES
Treuner, Kai, San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070112017	A1	20070517
APPLICATION INFO.:	US 2006-554315	A1	20061030 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-731947P	20051031 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Page(s)
LINE COUNT: 4793
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a GABA agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 16 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2007:89508 USPATFULL
TITLE: MODULATION OF NEUORGENESIS BY HDac INHIBITION
INVENTOR(S): Barlow, Carrolee, Del Mar, CA, UNITED STATES
Carter, Todd A., San Diego, CA, UNITED STATES
Lorrain, Kym I., San Diego, CA, UNITED STATES
Pires, Jammieson C., San Diego, CA, UNITED STATES
Morse, Andrew, San Diego, CA, UNITED STATES
Gitnick, Dana, San Marcos, CA, UNITED STATES
Treuner, Kai, San Diego, CA, UNITED STATES
Dearie, Alejandro R., Chula Vista, CA, UNITED STATES
PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070078083	A1	20070405
APPLICATION INFO.:	US 2006-470957	A1	20060907 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-715219P	20050907 (60)
	US 2006-764963P	20060203 (60)
	US 2006-785713P	20060324 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 5466
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating

or increasing neurogenesis. The disclosure includes compositions and methods based on an HDac inhibitory agent alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 17 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2007:56630 USPATFULL
TITLE: NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION
INVENTOR(S): Barlow, Carrolee, Del Mar, CA, UNITED STATES
Carter, Tood A., San Diego, CA, UNITED STATES
Lorrain, Kym I., San Diego, CA, UNITED STATES
Pires, Jammieson C., San Diego, CA, UNITED STATES
Morse, Andrew, San Diego, CA, UNITED STATES
Gitnick, Dana, San Marcos, CA, UNITED STATES
Treuner, Kai, San Diego, CA, UNITED STATES
Broadhead, Alex, San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070049576	A1	20070301
APPLICATION INFO.:	US 2006-467527	A1	20060825 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-711846P	20050826 (60)
	US 2005-727127P	20051014 (60)
	US 2005-738133P	20051117 (60)
	US 2006-803826P	20060602 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Page(s)
LINE COUNT: 4031
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 18 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2006:341526 USPATFULL
TITLE: Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
INVENTOR(S): Thor, Karl Bruce, Cary, NC, UNITED STATES
Ricca, Daniel J., Rougemont, NC, UNITED STATES
PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., Waltham, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION: US 20060293309 A1 20061228
APPLICATION INFO.: US 2006-389887 A1 20060327 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-666253P	20050328 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, LLP, ONE POST OFFICE SQUARE, BOSTON, MA, 02109-2127, US
NUMBER OF CLAIMS: 101
EXEMPLARY CLAIM: 1
LINE COUNT: 4659
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The instant invention features compounds, for example, 5-HT.sub.3 receptor antagonists, having a peripherally restricted mode of action such that the compounds affect 5-HT.sub.3 receptors of the peripheral nervous system with diminished or reduced effects in the central nervous system. The compounds are particularly useful in treating disorders or conditions ameliorated by antagonism of peripheral 5-HT.sub.3 receptors. Moreover, side-effects attributable to antagonism of central 5-HT.sub.3 receptors can be lessened or reduced using the peripherally restricted compounds of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 99487-26-0D, MCI 225, quaternary ammonium derivs.
(MCI-225 quaternary ammonium derivative peripherally restricted 5-HT3 antagonists for treatment of disorders and conditions)
RN 99487-26-0 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 99487-25-9
(MCI-225 quaternary ammonium derivative peripherally restricted 5-HT3 antagonists for treatment of disorders and conditions)
RN 99487-25-9 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



L5 ANSWER 19 OF 22 USPATFULL on STN

ACCESSION NUMBER:	2006:196249 USPATFULL		
TITLE:	New therapeutic uses of (4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno [2,3-d] pyrimidine		
INVENTOR(S):	Cavalla, David, Cambridge, UNITED KINGDOM Gristwood, Robert William, Cambridge, UNITED KINGDOM		

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20060167005	A1	20060727	
APPLICATION INFO.:	US 2003-525532	A1	20030828	(10)
	WO 2003-GB3720		20030828	
			20050725	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2002-20064	20020829
	GB 2003-16115	20030709

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, PO BOX 142950, GAINESVILLE, FL, 32614-2950, US
NUMBER OF CLAIMS:	21
EXEMPLARY CLAIM:	1-15
LINE COUNT:	225

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB (4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)Thieno[2,3-D]Pyrimidine or a salt thereof has value in the treatment of fibromyalgia, obesity, weight gain and other conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99487-25-9 476148-82-0
(therapeutic uses of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-d]pyrimidine)

RN 99487-25-9 USPATFULL

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



RN 476148-82-0 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride, hydrate (1:1:1) (CA INDEX NAME)



● HCl

● H_2O

L5 ANSWER 20 OF 22 USPATFULL on STN

ACCESSION NUMBER:	2004:321517 USPATFULL
TITLE:	Method of treating nausea, vomiting, retching or any combination thereof
INVENTOR(S):	Landau, Steven B., Wellesley, MA, UNITED STATES Miller, Cheryl L., Natick, MA, UNITED STATES Thor, Karl B., Morrisville, NC, UNITED STATES
PATENT ASSIGNEE(S):	Dynogen, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040254172	A1	20041216
	US 7094786	B2	20060822
APPLICATION INFO.:	US 2004-846979	A1	20040514 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-757981, filed on 13 Jan 2004, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-492478P	20030804 (60)
	US 2003-440076P	20030113 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION

LEGAL REPRESENTATIVE: JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: CLM-01-70
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 1783
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT.sub.3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT.sub.3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 99487-25-9 99487-25-9D, salts
(method of treating nausea, vomiting, or retching by administering a 5-HT3 receptor antagonist and noradrenaline reuptake inhibitor)
RN 99487-25-9 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



RN 99487-25-9 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



L5 ANSWER 21 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2004:321516 USPATFULL
TITLE: Method of treating nausea, vomiting, retching or any combination thereof
INVENTOR(S): Landau, Steven B., Wellesley, MA, UNITED STATES
Miller, Cheryl L., Natick, MA, UNITED STATES

Thor, Karl B., Morrisville, NC, UNITED STATES
PATENT ASSIGNEE(S): Dynogen, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040254171	A1	20041216
APPLICATION INFO.:	US 2004-846978	A1	20040514 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-757981, filed on 13 Jan 2004, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-492478P	20030804 (60)
	US 2003-440076P	20030113 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017
NUMBER OF CLAIMS: 89
EXEMPLARY CLAIM: CLM-01-70
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 1991
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT.sub.3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT.sub.3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 99487-25-9 99487-25-9D, salts
(method of treating nausea, vomiting, or retching by administering a 5-HT3 receptor antagonist and noradrenaline reuptake inhibitor)
RN 99487-25-9 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



RN 99487-25-9 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



L5 ANSWER 22 OF 22 USPATFULL on STN

ACCESSION NUMBER:	2004:190737 USPATFULL		
TITLE:	Method of treating nausea, vomiting, retching or any combination thereof		
INVENTOR(S):	Landau, Steven B., Wellesley, MA, UNITED STATES Miller, Cheryl L., Natick, MA, UNITED STATES Thor, Karl B., Morrisville, NC, UNITED STATES		
PATENT ASSIGNEE(S):	Dynogen Pharmaceuticals, Inc., Boston, MA (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040147510	A1	20040729
APPLICATION INFO.:	US 2004-757981	A1	20040113 (10)
	NUMBER	DATE	
PRIORITY INFORMATION:	US 2003-492478P	20030804 (60)	
	US 2003-440076P	20030113 (60)	
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133		
NUMBER OF CLAIMS:	70		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Page(s)		
LINE COUNT:	2041		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT.sub.3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT.sub.3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99487-25-9 99487-25-9D, salts
(method of treating nausea, vomiting, or retching by administering a 5-HT3 receptor antagonist and noradrenaline reuptake inhibitor)

RN 99487-25-9 USPATFULL

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



RN 99487-25-9 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-
(CA INDEX NAME)




```
=> d his

     (FILE 'HOME' ENTERED AT 14:22:34 ON 07 OCT 2008)

     FILE 'REGISTRY' ENTERED AT 14:22:41 ON 07 OCT 2008
L1              STRUCTURE UPLOADED
L2            0 S L1 EXA
L3            4 S L1 FUL

     FILE 'USPATFULL' ENTERED AT 14:23:31 ON 07 OCT 2008
L4           39 S L3
L5           22 S L4 AND CANCER

=> s l3 and chemotherapy
            39 L3
         46084 CHEMOTHERAPY
L6          21 L3 AND CHEMOTHERAPY

=> s l3 and chemotherapeutic
            39 L3
         35633 CHEMOTHERAPEUTIC
L7           7 L3 AND CHEMOTHERAPEUTIC

=> d l7 1-7 ibib, abs, hitstr

L7   ANSWER 1 OF 7  USPATFULL on STN
ACCESSION NUMBER:       2007:291200  USPATFULL
TITLE:                  Soluble salts of thieno[2,3-d]pyrimidine derivatives
INVENTOR(S):            Cooper, Martin Ian, Cambridgeshire, UNITED KINGDOM
                        Frampton, Christopher Stephen, Suffolk, UNITED KINGDOM
PATENT ASSIGNEE(S):     Dynogen Pharmaceuticals, Inc., Waltham, MA, UNITED
                        STATES, 02451 (U.S. corporation)
```

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070254899	A1	20071101
APPLICATION INFO.:	US 2007-728966	A1	20070327 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-788565P	20060331 (60)
	US 2006-808905P	20060526 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, LLP, ONE POST OFFICE SQUARE, BOSTON, MA, 02109-2127, US
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 2940
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to novel salts of thieno[2,3-d]pyrimidine derivatives, including 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts. The present invention is also directed to compositions including such polymorphs and methods for using such salts, e.g., in the treatment of gastrointestinal and/or genitourinary disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 99487-26-0, MCI-225
(soluble salts of thienopyrimidine derivs., and therapeutic use)
RN 99487-26-0 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 99487-25-9D, salts
(soluble salts of thienopyrimidine derivs., and therapeutic use)
RN 99487-25-9 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



IT 99487-25-9
(soluble salts of thienopyrimidine derivs., and therapeutic use)
RN 99487-25-9 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-
(CA INDEX NAME)



L7 ANSWER 2 OF 7 USPATFULL on STN

ACCESSION NUMBER:	2007:291192 USPATFULL
TITLE:	Crystalline forms of 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine
INVENTOR(S):	Cooper, Martin Ian, Cambridgeshire, UNITED KINGDOM Frampton, Christopher Stephen, Suffolk, UNITED KINGDOM
PATENT ASSIGNEE(S):	Dynogen Pharmaceuticals, Inc., Waltham, MA, UNITED STATES, 02451 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070254891	A1	20071101
APPLICATION INFO.:	US 2007-728947	A1	20070327 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-788338P	20060331 (60)
	US 2006-808603P	20060526 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, LLP, ONE POST OFFICE SQUARE, BOSTON, MA, 02109-2127, US
NUMBER OF CLAIMS:	33
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	11 Drawing Page(s)
LINE COUNT:	3877

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to novel crystalline forms of 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts, including 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine hydrochloride crystalline forms. The present

invention is also directed to compositions including such crystalline forms and methods for making and using such crystalline forms, e.g., in the treatment of gastrointestinal and/or genitourinary disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 99487-25-9D, salts 99487-26-0, MCI-225
(stable crystalline forms of 4-(2-fluorophenyl)-6-Me-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts for dosage forms)
RN 99487-25-9 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



RN 99487-26-0 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L7 ANSWER 3 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2007:89508 USPATFULL
TITLE: MODULATION OF NEUORGENESIS BY HDac INHIBITION
INVENTOR(S): Barlow, Carrolee, Del Mar, CA, UNITED STATES
Carter, Todd A., San Diego, CA, UNITED STATES
Lorrain, Kym I., San Diego, CA, UNITED STATES
Pires, Jammieson C., San Diego, CA, UNITED STATES
Morse, Andrew, San Diego, CA, UNITED STATES
Gitnick, Dana, San Marcos, CA, UNITED STATES
Treuner, Kai, San Diego, CA, UNITED STATES
Dearie, Alejandro R., Chula Vista, CA, UNITED STATES
PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES (U.S. corporation)

NUMBER	KIND	DATE

PATENT INFORMATION: US 20070078083 A1 20070405
APPLICATION INFO.: US 2006-470957 A1 20060907 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-715219P	20050907 (60)
	US 2006-764963P	20060203 (60)
	US 2006-785713P	20060324 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 5466
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on an HDac inhibitory agent alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2006:341526 USPATFULL
TITLE: Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
INVENTOR(S): Thor, Karl Bruce, Cary, NC, UNITED STATES
Ricca, Daniel J., Rougemont, NC, UNITED STATES
PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., Waltham, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060293309	A1	20061228
APPLICATION INFO.:	US 2006-389887	A1	20060327 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-666253P	20050328 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, LLP, ONE POST OFFICE SQUARE, BOSTON, MA, 02109-2127, US
NUMBER OF CLAIMS: 101
EXEMPLARY CLAIM: 1
LINE COUNT: 4659
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The instant invention features compounds, for example, 5-HT.sub.3 receptor antagonists, having a peripherally restricted mode of action such that the compounds affect 5-HT.sub.3 receptors of the peripheral nervous system with diminished or reduced effects in the central nervous system. The compounds are particularly useful in treating disorders or conditions ameliorated by antagonism of peripheral 5-HT.sub.3 receptors. Moreover, side-effects attributable to antagonism of central 5-HT.sub.3 receptors can be lessened or reduced using the peripherally restricted compounds of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99487-26-0D, MCI 225, quaternary ammonium derivs.
(MCI-225 quaternary ammonium derivative peripherally restricted 5-HT3 antagonists for treatment of disorders and conditions)
RN 99487-26-0 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 99487-25-9
(MCI-225 quaternary ammonium derivative peripherally restricted 5-HT3 antagonists for treatment of disorders and conditions)
RN 99487-25-9 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



L7 ANSWER 5 OF 7 USPATFULL on STN

ACCESSION NUMBER:	2004:321517 USPATFULL
TITLE:	Method of treating nausea, vomiting, retching or any combination thereof
INVENTOR(S):	Landau, Steven B., Wellesley, MA, UNITED STATES Miller, Cheryl L., Natick, MA, UNITED STATES Thor, Karl B., Morrisville, NC, UNITED STATES
PATENT ASSIGNEE(S):	Dynogen, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040254172	A1	20041216
	US 7094786	B2	20060822
APPLICATION INFO.:	US 2004-846979	A1	20040514 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-757981, filed on 13 Jan 2004, PENDING

	NUMBER	DATE

PRIORITY INFORMATION:	US 2003-492478P	20030804 (60)
	US 2003-440076P	20030113 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	CLM-01-70	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	1783	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT.sub.3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT.sub.3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99487-25-9 99487-25-9D, salts
(method of treating nausea, vomiting, or retching by administering a 5-HT3 receptor antagonist and noradrenaline reuptake inhibitor)

RN 99487-25-9 USPATFULL

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



RN 99487-25-9 USPATFULL

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



L7 ANSWER 6 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2004:321516 USPATFULL
TITLE: Method of treating nausea, vomiting, retching or any combination thereof
INVENTOR(S): Landau, Steven B., Wellesley, MA, UNITED STATES
Miller, Cheryl L., Natick, MA, UNITED STATES
Thor, Karl B., Morrisville, NC, UNITED STATES
PATENT ASSIGNEE(S): Dynogen, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040254171	A1	20041216
APPLICATION INFO.:	US 2004-846978	A1	20040514 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-757981, filed on 13 Jan 2004, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-492478P	20030804 (60)
	US 2003-440076P	20030113 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017
NUMBER OF CLAIMS: 89
EXEMPLARY CLAIM: CLM-01-70
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 1991
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT.sub.3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT.sub.3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 99487-25-9 99487-25-9D, salts
(method of treating nausea, vomiting, or retching by administering a 5-HT3 receptor antagonist and noradrenaline reuptake inhibitor)
RN 99487-25-9 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



RN 99487-25-9 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-

(CA INDEX NAME)



L7 ANSWER 7 OF 7 USPATFULL on STN

ACCESSION NUMBER:	2004:190737 USPATFULL
TITLE:	Method of treating nausea, vomiting, retching or any combination thereof
INVENTOR(S):	Landau, Steven B., Wellesley, MA, UNITED STATES Miller, Cheryl L., Natick, MA, UNITED STATES Thor, Karl B., Morrisville, NC, UNITED STATES
PATENT ASSIGNEE(S):	Dynogen Pharmaceuticals, Inc., Boston, MA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040147510	A1	20040729
APPLICATION INFO.:	US 2004-757981	A1	20040113 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-492478P	20030804 (60)
	US 2003-440076P	20030113 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133
NUMBER OF CLAIMS:	70
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	3 Drawing Page(s)
LINE COUNT:	2041

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT.sub.3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT.sub.3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99487-25-9 99487-25-9D, salts
(method of treating nausea, vomiting, or retching by administering a 5-HT3 receptor antagonist and noradrenaline reuptake inhibitor)

RN 99487-25-9 USPATFULL

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-

(CA INDEX NAME)



RN 99487-25-9 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-
(CA INDEX NAME)



=> s l3 and (nausea or vomit? or emesis)
39 L3
16816 NAUSEA
14017 VOMIT?
3851 EMESIS
L8 15 L3 AND (NAUSEA OR VOMIT? OR EMESIS)

=> d l8 1-15 ibib, abs, hitstr

L8 ANSWER 1 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2008:190889 USPATFULL
TITLE: NEUROGENESIS BY MODULATING ANGIOTENSIN
INVENTOR(S): Barlow, Carolee, Del Mar, CA, UNITED STATES
Carter, Todd A., San Diego, CA, UNITED STATES
Treuner, Kai, San Diego, CA, UNITED STATES
Lorrain, Kym I., San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20080167291	A1	20080710	
APPLICATION INFO.:	US 2007-746539	A1	20070509	(11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-746859P	20060509 (60)
	US 2006-807594P	20060717 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Page(s)
LINE COUNT: 5191
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The invention includes compositions and methods based on modulation angiotensin activity to stimulate or activate the formation of new nerve cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 2 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2008:175983 USPATFULL
TITLE: COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND ACETYLCHOLINESTERASE INHIBITION
INVENTOR(S): Lange, Josephus H.M., Weesp, NETHERLANDS
Kruse, Cornelis G., Weesp, NETHERLANDS
Shadid, Belal, Weesp, NETHERLANDS
PATENT ASSIGNEE(S): Solvay Pharmaceuticals B.V. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080153867	A1	20080626
APPLICATION INFO.:	US 2007-957948	A1	20071217 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-875808P	20061220 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 1612
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Embodiments of this invention relate to compounds having a combination of cannabinoid-CB.sub.1 antagonism and cholinesterase inhibition, to pharmaceutical compositions comprising these compounds, to methods for preparing these compounds, methods for preparing novel intermediates useful for the synthesis of these compounds, and methods for preparing compositions comprising these compounds. The invention also relates to methods of treating Alzheimer's disease, cognitive disorders, memory disorders, dementia, attention deficit disorder, traumatic brain injury, drug dependence, addiction or substance abuse by administering a pharmaceutical composition comprising these compounds to a patient in need thereof. A compound with a combination of cannabinoid-CB.sub.1 antagonism and cholinesterase inhibition is a compound of formula (1)

##STR1##

wherein the symbols have the meanings given in the specification.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 99487-26-0DP, MCI-225, pharmacophoric element, conjugates with CB1 antagonist pharmacophoric element
(preparation of compds. with both CB1 receptor antagonistic and acetylcholinesterase inhibiting activities)

RN 99487-26-0 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L8 ANSWER 3 OF 15 USPATFULL on STN

ACCESSION NUMBER:	2007:291200 USPATFULL		
TITLE:	Soluble salts of thieno[2,3-d]pyrimidine derivatives		
INVENTOR(S):	Cooper, Martin Ian, Cambridgeshire, UNITED KINGDOM Frampton, Christopher Stephen, Suffolk, UNITED KINGDOM		
PATENT ASSIGNEE(S):	Dynogen Pharmaceuticals, Inc., Waltham, MA, UNITED STATES, 02451 (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070254899	A1	20071101
APPLICATION INFO.:	US 2007-728966	A1	20070327 (11)
	NUMBER		DATE
PRIORITY INFORMATION:	US 2006-788565P		20060331 (60)
	US 2006-808905P		20060526 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, LLP, ONE POST OFFICE SQUARE, BOSTON, MA, 02109-2127, US		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	2940		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to novel salts of thieno[2,3-d]pyrimidine derivatives, including 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts. The present invention is also directed to compositions including such polymorphs and methods for using such salts, e.g., in the treatment of gastrointestinal and/or genitourinary disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99487-26-0, MCI-225
(soluble salts of thienopyrimidine derivs., and therapeutic use)

RN 99487-26-0 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 99487-25-9D, salts
(soluble salts of thienopyrimidine derivs., and therapeutic use)
RN 99487-25-9 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-
(CA INDEX NAME)



IT 99487-25-9
(soluble salts of thienopyrimidine derivs., and therapeutic use)
RN 99487-25-9 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-
(CA INDEX NAME)



L8 ANSWER 4 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2007:291192 USPATFULL
TITLE: Crystalline forms of 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine
INVENTOR(S): Cooper, Martin Ian, Cambridgeshire, UNITED KINGDOM
Frampton, Christopher Stephen, Suffolk, UNITED KINGDOM
PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., Waltham, MA, UNITED STATES, 02451 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070254891	A1	20071101
APPLICATION INFO.:	US 2007-728947	A1	20070327 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-788338P	20060331 (60)
	US 2006-808603P	20060526 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, LLP, ONE POST OFFICE SQUARE, BOSTON, MA, 02109-2127, US
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Page(s)
LINE COUNT: 3877
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to novel crystalline forms of 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts, including 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine hydrochloride crystalline forms. The present invention is also directed to compositions including such crystalline forms and methods for making and using such crystalline forms, e.g., in the treatment of gastrointestinal and/or genitourinary disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 99487-25-9D, salts 99487-26-0, MCI-225
(stable crystalline forms of 4-(2-fluorophenyl)-6-Me-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts for dosage forms)
RN 99487-25-9 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



RN 99487-26-0 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L8 ANSWER 5 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2007:237654 USPATFULL
TITLE: MODULATION OF NEUROGENESIS BY PDE INHIBITION
INVENTOR(S): Barlow, Carrolee, Del Mar, CA, UNITED STATES
Carter, Todd A., San Diego, CA, UNITED STATES
Lorrain, Kym I., San Diego, CA, UNITED STATES
Pires, Jammieson C., San Diego, CA, UNITED STATES
Treuner, Kai, San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070208029	A1	20070906
APPLICATION INFO.:	US 2006-551667	A1	20061020 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-729366P	20051021 (60)
	US 2006-784605P	20060321 (60)
	US 2006-807594P	20060717 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 4538
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a PDE agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2007:128661 USPATFULL
TITLE: GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS
INVENTOR(S): Barlow, Carrolee, Del Mar, CA, UNITED STATES
Carter, Todd A., San Diego, CA, UNITED STATES

Morse, Andrew, San Diego, CA, UNITED STATES
Lorrain, Kym I., San Diego, CA, UNITED STATES
Pires, Jammieson C., San Diego, CA, UNITED STATES
Treuner, Kai, San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070112017	A1	20070517
APPLICATION INFO.:	US 2006-554315	A1	20061030 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-731947P	20051031 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Page(s)
LINE COUNT: 4793
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a GABA agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2007:56630 USPATFULL
TITLE: NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION
INVENTOR(S): Barlow, Carrolee, Del Mar, CA, UNITED STATES
Carter, Tood A., San Diego, CA, UNITED STATES
Lorrain, Kym I., San Diego, CA, UNITED STATES
Pires, Jammieson C., San Diego, CA, UNITED STATES
Morse, Andrew, San Diego, CA, UNITED STATES
Gitnick, Dana, San Marcos, CA, UNITED STATES
Treuner, Kai, San Diego, CA, UNITED STATES
Broadhead, Alex, San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070049576	A1	20070301
APPLICATION INFO.:	US 2006-467527	A1	20060825 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-711846P	20050826 (60)
	US 2005-727127P	20051014 (60)
	US 2005-738133P	20051117 (60)
	US 2006-803826P	20060602 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US

NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Page(s)
LINE COUNT: 4031
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2006:341526 USPATFULL
TITLE: Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
INVENTOR(S): Thor, Karl Bruce, Cary, NC, UNITED STATES
Ricca, Daniel J., Rougemont, NC, UNITED STATES
PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., Waltham, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060293309	A1	20061228
APPLICATION INFO.:	US 2006-389887	A1	20060327 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-666253P	20050328 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, LLP, ONE POST OFFICE SQUARE, BOSTON, MA, 02109-2127, US
NUMBER OF CLAIMS: 101
EXEMPLARY CLAIM: 1
LINE COUNT: 4659
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The instant invention features compounds, for example, 5-HT.sub.3 receptor antagonists, having a peripherally restricted mode of action such that the compounds affect 5-HT.sub.3 receptors of the peripheral nervous system with diminished or reduced effects in the central nervous system. The compounds are particularly useful in treating disorders or conditions ameliorated by antagonism of peripheral 5-HT.sub.3 receptors. Moreover, side-effects attributable to antagonism of central 5-HT.sub.3 receptors can be lessened or reduced using the peripherally restricted compounds of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 99487-26-0D, MCI 225, quaternary ammonium derivs.
(MCI-225 quaternary ammonium derivative peripherally restricted 5-HT3 antagonists for treatment of disorders and conditions)
RN 99487-26-0 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 99487-25-9
(MCI-225 quaternary ammonium derivative peripherally restricted 5-HT3 antagonists for treatment of disorders and conditions)
RN 99487-25-9 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



L8 ANSWER 9 OF 15 USPATFULL on STN

ACCESSION NUMBER:	2006:196249 USPATFULL			
TITLE:	New therapeutic uses of (4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno [2,3-d] pyrimidine			
INVENTOR(S):	Cavalla, David, Cambridge, UNITED KINGDOM Gristwood, Robert William, Cambridge, UNITED KINGDOM			

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20060167005	A1	20060727	
APPLICATION INFO.:	US 2003-525532	A1	20030828	(10)
	WO 2003-GB3720		20030828	
			20050725	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2002-20064	20020829
	GB 2003-16115	20030709

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, PO BOX 142950, GAINESVILLE, FL, 32614-2950, US
NUMBER OF CLAIMS:	21
EXEMPLARY CLAIM:	1-15

LINE COUNT: 225
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB (4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)Thieno[2,3-D]Pyrimidine or a salt thereof has value in the treatment of fibromyalgia, obesity, weight gain and other conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 99487-25-9 476148-82-0
(therapeutic uses of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-d]pyrimidine)
RN 99487-25-9 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



RN 476148-82-0 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride, hydrate (1:1:1) (CA INDEX NAME)



● HCl

● H_2O

L8 ANSWER 10 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2005:275228 USPATFULL
TITLE: 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-d)pyrimidine in the treatment of functional bowel disorder
INVENTOR(S): Cavalla, David, Cambridge, UNITED KINGDOM
Gristwood, Robert William, Cambridge, UNITED KINGDOM

NUMBER KIND DATE

PATENT INFORMATION:	US 20050239792	A1	20051027
APPLICATION INFO.:	US 2003-519594	A1	20030709 (10)
	WO 2003-GB2974		20030709
			20041228 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2002-16027	20020710

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, PO BOX 142950, GAINESVILLE, FL, 32614-2950, US
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 160
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Use of 4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)Thieno[2,3-D]Pyrimidine or a salt thereof for the manufacture of a medicament for the treatment of functional bowel disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 99487-25-9 99487-26-0, MCI 225 476148-82-0
(thienopyrimidine deriv.for treatment of pain)
RN 99487-25-9 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



RN 99487-26-0 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 476148-82-0 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride, hydrate (1:1:1) (CA INDEX NAME)



● HCl

● H_2O

L8 ANSWER 11 OF 15 USPATFULL on STN

ACCESSION NUMBER:	2005:255664 USPATFULL		
TITLE:	Use of 4-(2-flurophenyl)-6-methyl-2-(1-piperazinyl)thieno(2,3-d)-pyrimidine for treating of urinary incontinence		
INVENTOR(S):	Cavalla, David, Cambridge, UNITED KINGDOM Gristwood, Robert William, Cambridge, UNITED KINGDOM		

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20050222162	A1	20051006	
	US 7220748	B2	20070522	
APPLICATION INFO.:	US 2003-502827	A1	20030129	(10)
	WO 2003-GB374		20030129	
			20040727	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2002-2265	20020131

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, PO BOX 142950, GAINESVILLE, FL, 32614-2950, US
NUMBER OF CLAIMS:	3
EXEMPLARY CLAIM:	1
LINE COUNT:	168

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)-Thieno(2,3-D)pyrimidine or a salt thereof is useful for the treatment of urinary incontinence.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99487-25-9 99487-26-0, MCI 225 476148-82-0
(piperazinylthienopyrimidine derivative for treating urinary incontinence)

RN 99487-25-9 USPATFULL

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-
(CA INDEX NAME)



RN 99487-26-0 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 476148-82-0 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-,
hydrochloride, hydrate (1:1:1) (CA INDEX NAME)



● HCl

● H_2O

L8 ANSWER 12 OF 15 USPATFULL on STN

ACCESSION NUMBER:	2004:321517 USPATFULL
TITLE:	Method of treating nausea, vomiting , retching or any combination thereof
INVENTOR(S):	Landau, Steven B., Wellesley, MA, UNITED STATES Miller, Cheryl L., Natick, MA, UNITED STATES Thor, Karl B., Morrisville, NC, UNITED STATES
PATENT ASSIGNEE(S):	Dynogen, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040254172	A1	20041216
	US 7094786	B2	20060822
APPLICATION INFO.:	US 2004-846979	A1	20040514 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-757981, filed on 13 Jan 2004, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-492478P	20030804 (60)
	US 2003-440076P	20030113 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017
NUMBER OF CLAIMS:	7
EXEMPLARY CLAIM:	CLM-01-70
NUMBER OF DRAWINGS:	3 Drawing Page(s)
LINE COUNT:	1783

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT.sub.3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT.sub.3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99487-25-9 99487-25-9D, salts
(method of treating nausea, vomiting, or retching by administering a 5-HT3 receptor antagonist and noradrenaline reuptake inhibitor)

RN 99487-25-9 USPATFULL

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



RN 99487-25-9 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-
(CA INDEX NAME)



L8 ANSWER 13 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2004:321516 USPATFULL
TITLE: Method of treating nausea, vomiting
, retching or any combination thereof
INVENTOR(S): Landau, Steven B., Wellesley, MA, UNITED STATES
Miller, Cheryl L., Natick, MA, UNITED STATES
Thor, Karl B., Morrisville, NC, UNITED STATES
PATENT ASSIGNEE(S): Dynogen, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040254171	A1	20041216
APPLICATION INFO.:	US 2004-846978	A1	20040514 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-757981, filed on 13
Jan 2004, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-492478P	20030804 (60)
	US 2003-440076P	20030113 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017
NUMBER OF CLAIMS: 89
EXEMPLARY CLAIM: CLM-01-70
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 1991
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a method of treating nausea,
vomiting, retching or any combination thereof in a subject in
need of treatment. The method comprises administering to a subject in
need of treatment a therapeutically effective amount of a compound that
has 5-HT.sub.3 receptor antagonist activity and NorAdrenaline Reuptake

Inhibitor (NARI) activity. The invention further relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT.sub.3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 99487-25-9 99487-25-9D, salts
(method of treating nausea, vomiting, or retching by administering a 5-HT3 receptor antagonist and noradrenaline reuptake inhibitor)
RN 99487-25-9 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



RN 99487-25-9 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



L8 ANSWER 14 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2004:190737 USPATFULL
TITLE: Method of treating nausea, vomiting , retching or any combination thereof
INVENTOR(S): Landau, Steven B., Wellesley, MA, UNITED STATES
Miller, Cheryl L., Natick, MA, UNITED STATES
Thor, Karl B., Morrisville, NC, UNITED STATES
PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., Boston, MA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040147510	A1	20040729
APPLICATION INFO.:	US 2004-757981	A1	20040113 (10)

NUMBER DATE

PRIORITY INFORMATION:	US 2003-492478P	20030804 (60)
	US 2003-440076P	20030113 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133	
NUMBER OF CLAIMS:	70	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	2041	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT.sub.3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT.sub.3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99487-25-9 99487-25-9D, salts
(method of treating nausea, vomiting, or retching by administering a 5-HT3 receptor antagonist and noradrenaline reuptake inhibitor)

RN 99487-25-9 USPATFULL

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



RN 99487-25-9 USPATFULL

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



L8 ANSWER 15 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2004:64355 USPATFULL
TITLE: New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
INVENTOR(S): Bardsley, Hazel Judith, Konstanz, GERMANY, FEDERAL REPUBLIC OF
Cavalla, David, Cambridge, UNITED KINGDOM
Gristwood, Robert William, Cambridge, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040048874	A1	20040311
APPLICATION INFO.:	US 2003-617847	A1	20030710 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2002-GB2388, filed on 21 May 2002, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2002-112494	20020522
	GB 2002-16027	20020710

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
LINE COUNT: 246
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine or a salt thereof is useful for the treatment of pain.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 99487-25-9 99487-26-0, MCI-225 476148-82-0
(fluorophenylmethylpiperazinylthienopyrimidine for treatment of pain)
RN 99487-25-9 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



RN 99487-26-0 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 476148-82-0 USPATFULL
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride, hydrate (1:1:1) (CA INDEX NAME)



● HCl

● H_2O

```
=> d his

     (FILE 'HOME' ENTERED AT 14:22:34 ON 07 OCT 2008)

     FILE 'REGISTRY' ENTERED AT 14:22:41 ON 07 OCT 2008
L1             STRUCTURE UPLOADED
L2           0 S L1 EXA
L3           4 S L1 FUL

     FILE 'USPATFULL' ENTERED AT 14:23:31 ON 07 OCT 2008
L4          39 S L3
L5          22 S L4 AND CANCER
L6          21 S L3 AND CHEMOTHERAPY
L7           7 S L3 AND CHEMOTHERAPEUTIC
L8          15 S L3 AND (NAUSEA OR VOMIT? OR EMESIS)

=>
```

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	209.47	396.04

STN INTERNATIONAL LOGOFF AT 14:30:29 ON 07 OCT 2008